Asthma

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Retrieved on: 
Tuesday, April 23, 2024
FDA, DSM-IV codes, Prurigo nodularis, Fast track (FDA), Safety, Risk, ITP, Food, Thrombocytopenia, Orphan, Research and development, Development, Patient, Fatigue, Intracranial hemorrhage, LUNA, Asthma, Sanofi, Hematology, BTK, IgG4-related disease

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).

Key Points: 
  • Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).
  • The safety profile of rilzabrutinib was consistent with that reported in previous studies.
  • LUNA 3 study met its primary endpoint demonstrating a significantly higher proportion of patients receiving rilzabrutinib achieved the primary endpoint of durable platelet response versus placebo.
  • This clinically and statistically significant result was achieved in a population of patients with primary ITP that had been refractory to prior therapy.

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 16, 2024
SCI, FDA, Congress, American Academy, Investment, RAD, NDA, Insurance, Partnership, Research, Week, Patient, AAD, Atopic dermatitis, Arena Pharmaceuticals, Inflammation, Accounting, Annual general meeting, Asthma, Inflammatory Bowel Diseases, Type, Connect, UC, Pharmaceutical industry

Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .

Key Points: 
  • Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .
  • Four posters at the 2023 World Congress of Dermatology in July 2023 on data from the initial 16-week treatment period with rademikibart of the pivotal trial in China in patients with moderate-to-severe AD.
  • Connect expects to receive an update from Simcere as early as Q2 2024 on these next steps.
  • Cash, cash equivalents and short-term investments were $118.7 million as of December 31, 2023, compared with $161.9 million on December 31, 2022.

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
Tuesday, April 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR

Retrieved on: 
Monday, April 15, 2024
AIR, U.S. AIR, Chronic obstructive pulmonary disease, Health, Leo Pharma, History, Smith, Patient, Asthma, Organization, COPD

Chiesi USA remains steadfast in its preparations for the full-scale U.S. launch of its AIR franchise as part of the company’s commitment to improving respiratory care and health in communities

Key Points: 
  • Chiesi USA remains steadfast in its preparations for the full-scale U.S. launch of its AIR franchise as part of the company’s commitment to improving respiratory care and health in communities
    CARY, N.C., April 15, 2024 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
  • Smith will report to Jon Zwinski, CEO and general manager of Chiesi USA.
  • “Richard’s inspirational leadership and track record of enabling actionable programs with multistakeholder engagement reflect Chiesi USA’s mission and values.
  • Before joining Chiesi USA, Smith was vice president and head of the U.S. commercial organization at LEO Pharma, Inc.

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma

Retrieved on: 
Thursday, May 2, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Hospitals, Other Health, Public, Society, Risk, GINA, MD, Doctor of Philosophy, Global Initiative for Asthma, Allergen, AIT, Patient, Allergic rhinitis, Pulmonology, Asthma, Quality of life, Pharmaceutical industry

The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.

Key Points: 
  • The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.
  • “Exploring the impact of allergen immunotherapy on asthma onset and progression is crucial, and we're committed to filling those gaps.
  • Through this real-world EfficAPSI study, Stallergenes Greer is honoured to contribute valuable scientific evidence and insights to allergy treatment.
  • By demonstrating the benefit on the onset and worsening of asthma, Stallergenes Greer SLIT-liquid treatments confirm their impact in terms of public health.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis

Retrieved on: 
Tuesday, April 30, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hemoptysis, MCID, Inflammation, Safety, Mucus, QOL, Professor, Bronchiectasis, MD, Doctor of Philosophy, Conference, Mycobacterium, Sputum, Periodic breathing, Urinary tract infection, CAAT, Disease, Chronic cough, Patient, Principal, Aes, Diagnosis, Inc., ITT, American Thoracic Society, Quality of life, Asthma, Bronchitis, National Jewish Health, Division, Infection, COPD, Pharmaceutical industry

The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.

Key Points: 
  • The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.
  • Participants were randomized (7:3, treatment:placebo), and 40 participants completed the study, with 29 completing in the ARINA-1 arm and 11 in the placebo (0.9% saline) arm.
  • Topline results from the intention-to-treat (ITT) population demonstrate that ARINA-1 is safe and improves quality of life (QOL) in individuals with NCFBE who experience mucus symptoms.
  • Renovion will discuss study results at the American Thoracic Society Meeting (May 17-22) and present findings at the World Bronchiectasis Conference (July 4-6) in Dundee, Scotland.

NuvoAir Medical Partners with Privia Medical Group — Georgia to Help Transform Cardiopulmonary Care with Virtual-First Care Model

Retrieved on: 
Tuesday, April 30, 2024
Nursing, Health, Practice Management, Health Technology, Other Health, General Health, Cardiology, PMG, Accountable care organization, Heart, Communication, Partnership, Asthma, Patient, Physician, ACO, CHF, Multimedia, COPD

This collaboration marks a significant step forward in enhancing access to high-quality cardiopulmonary care for patients throughout the state of Georgia.

Key Points: 
  • This collaboration marks a significant step forward in enhancing access to high-quality cardiopulmonary care for patients throughout the state of Georgia.
  • Privia operates the state’s highest performing Accountable Care Organization (ACO), with more than 380 providers caring for over 515,000 patients.
  • "We are thrilled to have NuvoAir Medical partner with PMG — Georgia to enhance our capabilities in delivering comprehensive, cardiopulmonary care to our patients," said PMG — Georgia’s Chief Medical Officer, Dr. Zia Khan.
  • The partnership between NuvoAir Medical and PMG represents a significant milestone in advancing the future of healthcare delivery and value-based care by combining clinical expertise with cutting-edge technology to help transform cardiopulmonary care for patients throughout the state.

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

Retrieved on: 
Monday, April 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bank of America, Congress, DEEP, ATS, Arrowhead, Antiviral Research, RESULTS, Conference, Asthma, EAS, NLA, National Lipid Association, AN, American Thoracic Society

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024
    BofA Securities 2024 Healthcare Conference – May 13-16, 2024
    TIDES USA 2024 – May 14-17, 2024
    American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024
    Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma
    37th International Conference on Antiviral Research (ICAR2024) – May 20-24, 2024
    European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024
    Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD
    2024 National Lipid Association (NLA) Scientific Sessions – May 30 – June 2, 2024
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Global Airway Management Devices Market Analysis and Forecast, 2023-2033: Competitive Landscape, Ecosystem, Reimbursement Scenario, Patent Analysis, Partnerships, Collaborations, & Business Expansions - ResearchAndMarkets.com

Retrieved on: 
Monday, April 29, 2024
General Health, Health, Medical Devices, Chronic obstructive pulmonary disease, Airway management, Competitive landscape, Catheter, Anesthesia, Asthma, Growth, Prevalence, COPD, Airline

North America is poised to emerge as a major contributor to the growth of the airway management devices market.

Key Points: 
  • North America is poised to emerge as a major contributor to the growth of the airway management devices market.
  • What are the major market drivers, challenges and opportunities in the global airway management devices market and their case studies?
  • What is the market share of the leading segments and sub-segments of the global airway management devices market?
  • How will each segment of the global airway management devices market grow during the forecast period?